Mount Sinai intends to continue its vigorous participation in activities with the Cancer and Leukemia Group B. We will commit intellectual and patient resources to research in acute leukemias, chronic leukemias, lymphomas, breast cancer, respiratory cancers, and companion studies with these clinical under takings involving cytogenetics, immunology and epidemiology. Various members of the Mount Sinai faculty will serve as Chairman of Studies, and bring some of their pilot observations conducted in the Mount Sinai Cancer Center to Group consideration. If adopted, such studies will serve as the feasibility pilot background for implementation on a broad multi- institutional basis, often in a comparative randomized study design. The objectives of the Group are to discover and validate effective treatment for the cure and long term palliation of cancer. Mount Sinai is wholeheartedly committed to these objectives, and will devote energy to make the most effective studies available to the Group for research purposes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA004457-31
Application #
3555815
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-04-01
Project End
1993-03-31
Budget Start
1990-04-06
Budget End
1991-03-31
Support Year
31
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Roman, Michael A; Koelwyn, Graeme J; Eves, Neil D et al. (2014) Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer. Respirology 19:105-8
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Kostakoglu, Lale; Schöder, Heiko; Johnson, Jeffrey L et al. (2012) Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma 53:2143-50
Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17
Ruddy, K J; Pitcher, B N; Archer, L E et al. (2012) Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol 23:3075-81

Showing the most recent 10 out of 87 publications